APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for Influenza

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antiviral Drugs for Influenza Market Analysis and Forecast 2026-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for Influenza Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for Influenza Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for Influenza Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for Influenza Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for Influenza Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for Influenza market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antiviral Drugs for Influenza include AdvaCare Pharma, Avexima, BioCryst Pharmaceuticals, Daiichi Sankyo, Morningside Pharmaceuticals, Shionogi, Wockhardt, GlaxoSmithKline and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antiviral Drugs for Influenza, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antiviral Drugs for Influenza, also provides the sales of main regions and countries. Of the upcoming market potential for Antiviral Drugs for Influenza, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiviral Drugs for Influenza sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antiviral Drugs for Influenza market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antiviral Drugs for Influenza sales, projected growth trends, production technology, application and end-user industry.

Antiviral Drugs for Influenza Segment by Company

AdvaCare Pharma

Avexima

BioCryst Pharmaceuticals

Daiichi Sankyo

Morningside Pharmaceuticals

Shionogi

Wockhardt

GlaxoSmithKline

Roche

Teva Pharmaceuticals

Antiviral Drugs for Influenza Segment by Type

Neuraminidase Inhibitors

Polymerase Inhibitors

Antiviral Drugs for Influenza Segment by Application

Over-the-counter (OTC)

Prescription (Rx)

Antiviral Drugs for Influenza Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for Influenza market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for Influenza and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for Influenza.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antiviral Drugs for Influenza in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiviral Drugs for Influenza sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antiviral Drugs for Influenza Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Neuraminidase Inhibitors Major Manufacturers Table 3. Polymerase Inhibitors Major Manufacturers Table 4. Global Antiviral Drugs for Influenza Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Over-the-counter (OTC) Major Manufacturers Table 6. Prescription (Rx) Major Manufacturers Table 7. Antiviral Drugs for Influenza Industry Trends Table 8. Antiviral Drugs for Influenza Industry Drivers Table 9. Antiviral Drugs for Influenza Industry Opportunities and Challenges Table 10. Antiviral Drugs for Influenza Industry Restraints Table 11. Global Antiviral Drugs for Influenza Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Antiviral Drugs for Influenza Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Antiviral Drugs for Influenza Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2021-2026) Table 15. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2027-2032) Table 16. Global Antiviral Drugs for Influenza Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Antiviral Drugs for Influenza Sales by Region (2021-2026) & (K Units) Table 18. Global Antiviral Drugs for Influenza Sales by Region (2027-2032) & (K Units) Table 19. Global Antiviral Drugs for Influenza Sales Market Share by Region (2021-2026) Table 20. Global Antiviral Drugs for Influenza Sales Market Share by Region (2027-2032) Table 21. Global Antiviral Drugs for Influenza Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Antiviral Drugs for Influenza Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Antiviral Drugs for Influenza Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Antiviral Drugs for Influenza Sales Market Share by Manufacturers (2021-2026) Table 25. Global Antiviral Drugs for Influenza Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Antiviral Drugs for Influenza Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Antiviral Drugs for Influenza Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Antiviral Drugs for Influenza Manufacturers, Product Type & Application Table 29. Global Antiviral Drugs for Influenza Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Antiviral Drugs for Influenza by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Antiviral Drugs for Influenza Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2026) Table 36. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2027-2032) Table 37. Global Antiviral Drugs for Influenza Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 39. Global Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 40. Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2026) Table 41. Global Antiviral Drugs for Influenza Sales Market Share by Type (2027-2032) Table 42. Global Antiviral Drugs for Influenza Price by Type (2021-2026) & (US$/Unit) Table 43. Global Antiviral Drugs for Influenza Price by Type (2027-2032) & (US$/Unit) Table 44. Global Antiviral Drugs for Influenza Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2026) Table 48. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2027-2032) Table 49. Global Antiviral Drugs for Influenza Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 51. Global Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 52. Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2026) Table 53. Global Antiviral Drugs for Influenza Sales Market Share by Application (2027-2032) Table 54. Global Antiviral Drugs for Influenza Price by Application (2021-2026) & (US$/Unit) Table 55. Global Antiviral Drugs for Influenza Price by Application (2027-2032) & (US$/Unit) Table 56. AdvaCare Pharma Company Information Table 57. AdvaCare Pharma Business Overview Table 58. AdvaCare Pharma Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio Table 60. AdvaCare Pharma Recent Development Table 61. Avexima Company Information Table 62. Avexima Business Overview Table 63. Avexima Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Avexima Antiviral Drugs for Influenza Product Portfolio Table 65. Avexima Recent Development Table 66. BioCryst Pharmaceuticals Company Information Table 67. BioCryst Pharmaceuticals Business Overview Table 68. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 70. BioCryst Pharmaceuticals Recent Development Table 71. Daiichi Sankyo Company Information Table 72. Daiichi Sankyo Business Overview Table 73. Daiichi Sankyo Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio Table 75. Daiichi Sankyo Recent Development Table 76. Morningside Pharmaceuticals Company Information Table 77. Morningside Pharmaceuticals Business Overview Table 78. Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 80. Morningside Pharmaceuticals Recent Development Table 81. Shionogi Company Information Table 82. Shionogi Business Overview Table 83. Shionogi Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shionogi Antiviral Drugs for Influenza Product Portfolio Table 85. Shionogi Recent Development Table 86. Wockhardt Company Information Table 87. Wockhardt Business Overview Table 88. Wockhardt Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Wockhardt Antiviral Drugs for Influenza Product Portfolio Table 90. Wockhardt Recent Development Table 91. GlaxoSmithKline Company Information Table 92. GlaxoSmithKline Business Overview Table 93. GlaxoSmithKline Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio Table 95. GlaxoSmithKline Recent Development Table 96. Roche Company Information Table 97. Roche Business Overview Table 98. Roche Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Roche Antiviral Drugs for Influenza Product Portfolio Table 100. Roche Recent Development Table 101. Teva Pharmaceuticals Company Information Table 102. Teva Pharmaceuticals Business Overview Table 103. Teva Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 105. Teva Pharmaceuticals Recent Development Table 106. North America Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (US$ Million) Table 107. North America Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (US$ Million) Table 108. North America Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 109. North America Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 110. North America Antiviral Drugs for Influenza Sales Price by Type (2021-2026) & (US$/Unit) Table 111. North America Antiviral Drugs for Influenza Sales Price by Type (2027-2032) & (US$/Unit) Table 112. North America Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 115. North America Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 116. North America Antiviral Drugs for Influenza Sales Price by Application (2021-2026) & (US$/Unit) Table 117. North America Antiviral Drugs for Influenza Sales Price by Application (2027-2032) & (US$/Unit) Table 118. North America Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 120. North America Antiviral Drugs for Influenza Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 121. North America Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 122. North America Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 123. North America Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 124. North America Antiviral Drugs for Influenza Sales Price by Country (2021-2026) & (US$/Unit) Table 125. North America Antiviral Drugs for Influenza Sales Price by Country (2027-2032) & (US$/Unit) Table 126. United States Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 127. Canada Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 128. Europe Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (US$ Million) Table 129. Europe Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (US$ Million) Table 130. Europe Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 131. Europe Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 132. Europe Antiviral Drugs for Influenza Sales Price by Type (2021-2026) & (US$/Unit) Table 133. Europe Antiviral Drugs for Influenza Sales Price by Type (2027-2032) & (US$/Unit) Table 134. Europe Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (US$ Million) Table 135. Europe Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (US$ Million) Table 136. Europe Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 137. Europe Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 138. Europe Antiviral Drugs for Influenza Sales Price by Application (2021-2026) & (US$/Unit) Table 139. Europe Antiviral Drugs for Influenza Sales Price by Application (2027-2032) & (US$/Unit) Table 140. Europe Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. Europe Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 142. Europe Antiviral Drugs for Influenza Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 143. Europe Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 144. Europe Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 145. Europe Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 146. Europe Antiviral Drugs for Influenza Sales Price by Country (2021-2026) & (US$/Unit) Table 147. Europe Antiviral Drugs for Influenza Sales Price by Country (2027-2032) & (US$/Unit) Table 148. Germany Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 149. France Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 150. U.K. Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 151. Italy Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 152. Netherlands Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 153. China Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (US$ Million) Table 154. China Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (US$ Million) Table 155. China Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 156. China Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 157. China Antiviral Drugs for Influenza Sales Price by Type (2021-2026) & (US$/Unit) Table 158. China Antiviral Drugs for Influenza Sales Price by Type (2027-2032) & (US$/Unit) Table 159. China Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (US$ Million) Table 160. China Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (US$ Million) Table 161. China Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 162. China Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 163. China Antiviral Drugs for Influenza Sales Price by Application (2021-2026) & (US$/Unit) Table 164. China Antiviral Drugs for Influenza Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Asia Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (US$ Million) Table 166. Asia Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (US$ Million) Table 167. Asia Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 168. Asia Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 169. Asia Antiviral Drugs for Influenza Sales Price by Type (2021-2026) & (US$/Unit) Table 170. Asia Antiviral Drugs for Influenza Sales Price by Type (2027-2032) & (US$/Unit) Table 171. Asia Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 174. Asia Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 175. Asia Antiviral Drugs for Influenza Sales Price by Application (2021-2026) & (US$/Unit) Table 176. Asia Antiviral Drugs for Influenza Sales Price by Application (2027-2032) & (US$/Unit) Table 177. Asia Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. Asia Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 179. Asia Antiviral Drugs for Influenza Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 180. Asia Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 181. Asia Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 182. Asia Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 183. Asia Antiviral Drugs for Influenza Sales Price by Country (2021-2026) & (US$/Unit) Table 184. Asia Antiviral Drugs for Influenza Sales Price by Country (2027-2032) & (US$/Unit) Table 185. Japan Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 186. South Korea Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 187. India Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 188. Australia Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 189. China Taiwan Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 190. Southeast Asia Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 191. SAMEA Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (US$ Million) Table 192. SAMEA Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (US$ Million) Table 193. SAMEA Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 194. SAMEA Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 195. SAMEA Antiviral Drugs for Influenza Sales Price by Type (2021-2026) & (US$/Unit) Table 196. SAMEA Antiviral Drugs for Influenza Sales Price by Type (2027-2032) & (US$/Unit) Table 197. SAMEA Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (US$ Million) Table 198. SAMEA Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (US$ Million) Table 199. SAMEA Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 200. SAMEA Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 201. SAMEA Antiviral Drugs for Influenza Sales Price by Application (2021-2026) & (US$/Unit) Table 202. SAMEA Antiviral Drugs for Influenza Sales Price by Application (2027-2032) & (US$/Unit) Table 203. SAMEA Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. SAMEA Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. SAMEA Antiviral Drugs for Influenza Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. SAMEA Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 207. SAMEA Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 208. SAMEA Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 209. SAMEA Antiviral Drugs for Influenza Sales Price by Country (2021-2026) & (US$/Unit) Table 210. SAMEA Antiviral Drugs for Influenza Sales Price by Country (2027-2032) & (US$/Unit) Table 211. Brazil Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 212. Argentina Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 213. Chile Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 214. Colombia Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 215. Peru Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 216. Saudi Arabia Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 217. Israel Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 218. UAE Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 219. Turkey Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 220. Iran Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 221. Egypt Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Antiviral Drugs for Influenza Distributors List Table 225. Antiviral Drugs for Influenza Customers List Table 226. Research Programs/Design for This Report Table 227. Authors List of This Report Table 228. Secondary Sources Table 229. Primary Sources List of Figures Figure 1. Antiviral Drugs for Influenza Image Figure 2. Global Antiviral Drugs for Influenza Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for Influenza Market Size Share 2021 VS 2025 VS 2032 Figure 4. Neuraminidase Inhibitors Image Figure 5. Polymerase Inhibitors Image Figure 6. Global Antiviral Drugs for Influenza Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Antiviral Drugs for Influenza Market Size Share 2021 VS 2025 VS 2032 Figure 8. Over-the-counter (OTC) Image Figure 9. Prescription (Rx) Image Figure 10. Global Antiviral Drugs for Influenza Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Figure 12. Global Antiviral Drugs for Influenza Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Antiviral Drugs for Influenza Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2021-2032) Figure 15. Global Antiviral Drugs for Influenza Sales (2021-2032) & (K Units) Figure 16. Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Antiviral Drugs for Influenza Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Antiviral Drugs for Influenza Sales YoY (2021-2032) & (K Units) Figure 19. Europe Antiviral Drugs for Influenza Sales YoY (2021-2032) & (K Units) Figure 20. China Antiviral Drugs for Influenza Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Antiviral Drugs for Influenza Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Antiviral Drugs for Influenza Sales YoY (2021-2032) & (K Units) Figure 23. Global Antiviral Drugs for Influenza Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Antiviral Drugs for Influenza Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Antiviral Drugs for Influenza Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Antiviral Drugs for Influenza Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2032) Figure 29. Global Antiviral Drugs for Influenza Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Antiviral Drugs for Influenza Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2032) Figure 32. Global Antiviral Drugs for Influenza Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Antiviral Drugs for Influenza Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2032) Figure 35. Global Antiviral Drugs for Influenza Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Antiviral Drugs for Influenza Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2032) Figure 38. North America Antiviral Drugs for Influenza Revenue Share by Type (2021-2032) Figure 39. North America Antiviral Drugs for Influenza Sales Share by Type (2021-2032) Figure 40. North America Antiviral Drugs for Influenza Revenue Share by Application (2021-2032) Figure 41. North America Antiviral Drugs for Influenza Sales Share by Application (2021-2032) Figure 42. North America Antiviral Drugs for Influenza Revenue Share by Country (2021-2032) Figure 43. North America Antiviral Drugs for Influenza Sales Share by Country (2021-2032) Figure 44. Europe Antiviral Drugs for Influenza Revenue Share by Type (2021-2032) Figure 45. Europe Antiviral Drugs for Influenza Sales Share by Type (2021-2032) Figure 46. Europe Antiviral Drugs for Influenza Revenue Share by Application (2021-2032) Figure 47. Europe Antiviral Drugs for Influenza Sales Share by Application (2021-2032) Figure 48. Europe Antiviral Drugs for Influenza Revenue Share by Country (2021-2032) Figure 49. Europe Antiviral Drugs for Influenza Sales Share by Country (2021-2032) Figure 50. China Antiviral Drugs for Influenza Revenue Share by Type (2021-2032) Figure 51. China Antiviral Drugs for Influenza Sales Share by Type (2021-2032) Figure 52. China Antiviral Drugs for Influenza Revenue Share by Application (2021-2032) Figure 53. China Antiviral Drugs for Influenza Sales Share by Application (2021-2032) Figure 54. Asia Antiviral Drugs for Influenza Revenue Share by Type (2021-2032) Figure 55. Asia Antiviral Drugs for Influenza Sales Share by Type (2021-2032) Figure 56. Asia Antiviral Drugs for Influenza Revenue Share by Application (2021-2032) Figure 57. Asia Antiviral Drugs for Influenza Sales Share by Application (2021-2032) Figure 58. Asia Antiviral Drugs for Influenza Revenue Share by Country (2021-2032) Figure 59. Asia Antiviral Drugs for Influenza Sales Share by Country (2021-2032) Figure 60. SAMEA Antiviral Drugs for Influenza Revenue Share by Type (2021-2032) Figure 61. SAMEA Antiviral Drugs for Influenza Sales Share by Type (2021-2032) Figure 62. SAMEA Antiviral Drugs for Influenza Revenue Share by Application (2021-2032) Figure 63. SAMEA Antiviral Drugs for Influenza Sales Share by Application (2021-2032) Figure 64. SAMEA Antiviral Drugs for Influenza Revenue Share by Country (2021-2032) Figure 65. SAMEA Antiviral Drugs for Influenza Sales Share by Country (2021-2032) Figure 66. Antiviral Drugs for Influenza Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Antiviral Drugs for Influenza Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors
Applications
  • Over-the-counter (OTC)
  • Prescription (Rx)
Companies covered
  • AdvaCare Pharma
  • Avexima
  • BioCryst Pharmaceuticals
  • Daiichi Sankyo
  • Morningside Pharmaceuticals
  • Shionogi
  • Wockhardt
  • GlaxoSmithKline
  • Roche
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antiviral Drugs for Influenza Market by Type
  3. 1.2.1 Global Antiviral Drugs for Influenza Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Neuraminidase Inhibitors
  5. 1.2.3 Polymerase Inhibitors
  6. 1.3 Antiviral Drugs for Influenza Market by Application
  7. 1.3.1 Global Antiviral Drugs for Influenza Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Over-the-counter (OTC)
  9. 1.3.3 Prescription (Rx)
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Antiviral Drugs for Influenza Market Dynamics
  1. 2.1 Antiviral Drugs for Influenza Industry Trends
  2. 2.2 Antiviral Drugs for Influenza Industry Drivers
  3. 2.3 Antiviral Drugs for Influenza Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for Influenza Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antiviral Drugs for Influenza Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antiviral Drugs for Influenza Revenue by Region
  3. 3.2.1 Global Antiviral Drugs for Influenza Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antiviral Drugs for Influenza Revenue by Region (2021-2026)
  5. 3.2.3 Global Antiviral Drugs for Influenza Revenue by Region (2027-2032)
  6. 3.2.4 Global Antiviral Drugs for Influenza Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antiviral Drugs for Influenza Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antiviral Drugs for Influenza Sales by Region
  9. 3.4.1 Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antiviral Drugs for Influenza Sales by Region (2021-2026)
  11. 3.4.3 Global Antiviral Drugs for Influenza Sales by Region (2027-2032)
  12. 3.4.4 Global Antiviral Drugs for Influenza Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antiviral Drugs for Influenza Revenue by Manufacturers
  2. 4.1.1 Global Antiviral Drugs for Influenza Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antiviral Drugs for Influenza Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antiviral Drugs for Influenza Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antiviral Drugs for Influenza Sales by Manufacturers
  6. 4.2.1 Global Antiviral Drugs for Influenza Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antiviral Drugs for Influenza Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antiviral Drugs for Influenza Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antiviral Drugs for Influenza Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antiviral Drugs for Influenza Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antiviral Drugs for Influenza Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antiviral Drugs for Influenza Manufacturers, Product Type & Application
  13. 4.7 Global Antiviral Drugs for Influenza Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antiviral Drugs for Influenza Market CR5 and HHI
  16. 4.8.2 2025 Antiviral Drugs for Influenza Tier 1, Tier 2, and Tier 3
5 Antiviral Drugs for Influenza Market by Type
  1. 5.1 Global Antiviral Drugs for Influenza Revenue by Type
  2. 5.1.1 Global Antiviral Drugs for Influenza Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antiviral Drugs for Influenza Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antiviral Drugs for Influenza Sales by Type
  6. 5.2.1 Global Antiviral Drugs for Influenza Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antiviral Drugs for Influenza Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antiviral Drugs for Influenza Price by Type
6 Antiviral Drugs for Influenza Market by Application
  1. 6.1 Global Antiviral Drugs for Influenza Revenue by Application
  2. 6.1.1 Global Antiviral Drugs for Influenza Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antiviral Drugs for Influenza Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antiviral Drugs for Influenza Sales by Application
  6. 6.2.1 Global Antiviral Drugs for Influenza Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antiviral Drugs for Influenza Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antiviral Drugs for Influenza Price by Application
7 Company Profiles
  1. 7.1 AdvaCare Pharma
  2. 7.1.1 AdvaCare Pharma Company Information
  3. 7.1.2 AdvaCare Pharma Business Overview
  4. 7.1.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
  6. 7.1.5 AdvaCare Pharma Recent Developments
  7. 7.2 Avexima
  8. 7.2.1 Avexima Company Information
  9. 7.2.2 Avexima Business Overview
  10. 7.2.3 Avexima Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Avexima Antiviral Drugs for Influenza Product Portfolio
  12. 7.2.5 Avexima Recent Developments
  13. 7.3 BioCryst Pharmaceuticals
  14. 7.3.1 BioCryst Pharmaceuticals Company Information
  15. 7.3.2 BioCryst Pharmaceuticals Business Overview
  16. 7.3.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  18. 7.3.5 BioCryst Pharmaceuticals Recent Developments
  19. 7.4 Daiichi Sankyo
  20. 7.4.1 Daiichi Sankyo Company Information
  21. 7.4.2 Daiichi Sankyo Business Overview
  22. 7.4.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
  24. 7.4.5 Daiichi Sankyo Recent Developments
  25. 7.5 Morningside Pharmaceuticals
  26. 7.5.1 Morningside Pharmaceuticals Company Information
  27. 7.5.2 Morningside Pharmaceuticals Business Overview
  28. 7.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  30. 7.5.5 Morningside Pharmaceuticals Recent Developments
  31. 7.6 Shionogi
  32. 7.6.1 Shionogi Company Information
  33. 7.6.2 Shionogi Business Overview
  34. 7.6.3 Shionogi Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
  36. 7.6.5 Shionogi Recent Developments
  37. 7.7 Wockhardt
  38. 7.7.1 Wockhardt Company Information
  39. 7.7.2 Wockhardt Business Overview
  40. 7.7.3 Wockhardt Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
  42. 7.7.5 Wockhardt Recent Developments
  43. 7.8 GlaxoSmithKline
  44. 7.8.1 GlaxoSmithKline Company Information
  45. 7.8.2 GlaxoSmithKline Business Overview
  46. 7.8.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
  48. 7.8.5 GlaxoSmithKline Recent Developments
  49. 7.9 Roche
  50. 7.9.1 Roche Company Information
  51. 7.9.2 Roche Business Overview
  52. 7.9.3 Roche Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Roche Antiviral Drugs for Influenza Product Portfolio
  54. 7.9.5 Roche Recent Developments
  55. 7.10 Teva Pharmaceuticals
  56. 7.10.1 Teva Pharmaceuticals Company Information
  57. 7.10.2 Teva Pharmaceuticals Business Overview
  58. 7.10.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  60. 7.10.5 Teva Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Antiviral Drugs for Influenza Market Size by Type
  2. 8.1.1 North America Antiviral Drugs for Influenza Revenue by Type (2021-2032)
  3. 8.1.2 North America Antiviral Drugs for Influenza Sales by Type (2021-2032)
  4. 8.1.3 North America Antiviral Drugs for Influenza Price by Type (2021-2032)
  5. 8.2 North America Antiviral Drugs for Influenza Market Size by Application
  6. 8.2.1 North America Antiviral Drugs for Influenza Revenue by Application (2021-2032)
  7. 8.2.2 North America Antiviral Drugs for Influenza Sales by Application (2021-2032)
  8. 8.2.3 North America Antiviral Drugs for Influenza Price by Application (2021-2032)
  9. 8.3 North America Antiviral Drugs for Influenza Market Size by Country
  10. 8.3.1 North America Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antiviral Drugs for Influenza Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Antiviral Drugs for Influenza Market Size by Type
  2. 9.1.1 Europe Antiviral Drugs for Influenza Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antiviral Drugs for Influenza Sales by Type (2021-2032)
  4. 9.1.3 Europe Antiviral Drugs for Influenza Price by Type (2021-2032)
  5. 9.2 Europe Antiviral Drugs for Influenza Market Size by Application
  6. 9.2.1 Europe Antiviral Drugs for Influenza Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antiviral Drugs for Influenza Sales by Application (2021-2032)
  8. 9.2.3 Europe Antiviral Drugs for Influenza Price by Application (2021-2032)
  9. 9.3 Europe Antiviral Drugs for Influenza Market Size by Country
  10. 9.3.1 Europe Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antiviral Drugs for Influenza Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Antiviral Drugs for Influenza Market Size by Type
  2. 10.1.1 China Antiviral Drugs for Influenza Revenue by Type (2021-2032)
  3. 10.1.2 China Antiviral Drugs for Influenza Sales by Type (2021-2032)
  4. 10.1.3 China Antiviral Drugs for Influenza Price by Type (2021-2032)
  5. 10.2 China Antiviral Drugs for Influenza Market Size by Application
  6. 10.2.1 China Antiviral Drugs for Influenza Revenue by Application (2021-2032)
  7. 10.2.2 China Antiviral Drugs for Influenza Sales by Application (2021-2032)
  8. 10.2.3 China Antiviral Drugs for Influenza Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antiviral Drugs for Influenza Market Size by Type
  2. 11.1.1 Asia Antiviral Drugs for Influenza Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antiviral Drugs for Influenza Sales by Type (2021-2032)
  4. 11.1.3 Asia Antiviral Drugs for Influenza Price by Type (2021-2032)
  5. 11.2 Asia Antiviral Drugs for Influenza Market Size by Application
  6. 11.2.1 Asia Antiviral Drugs for Influenza Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antiviral Drugs for Influenza Sales by Application (2021-2032)
  8. 11.2.3 Asia Antiviral Drugs for Influenza Price by Application (2021-2032)
  9. 11.3 Asia Antiviral Drugs for Influenza Market Size by Country
  10. 11.3.1 Asia Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antiviral Drugs for Influenza Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antiviral Drugs for Influenza Market Size by Type
  2. 12.1.1 SAMEA Antiviral Drugs for Influenza Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antiviral Drugs for Influenza Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antiviral Drugs for Influenza Price by Type (2021-2032)
  5. 12.2 SAMEA Antiviral Drugs for Influenza Market Size by Application
  6. 12.2.1 SAMEA Antiviral Drugs for Influenza Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antiviral Drugs for Influenza Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antiviral Drugs for Influenza Price by Application (2021-2032)
  9. 12.3 SAMEA Antiviral Drugs for Influenza Market Size by Country
  10. 12.3.1 SAMEA Antiviral Drugs for Influenza Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antiviral Drugs for Influenza Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antiviral Drugs for Influenza Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antiviral Drugs for Influenza Value Chain Analysis
  2. 13.1.1 Antiviral Drugs for Influenza Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antiviral Drugs for Influenza Production Mode & Process
  6. 13.2 Antiviral Drugs for Influenza Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antiviral Drugs for Influenza Distributors
  9. 13.2.3 Antiviral Drugs for Influenza Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst